Acer Therapeutics Shares Rise as China National Intellectual Property Administration Issued Utility Model Patent

Jul 8, 2022 By MarketDepth

Headlines Healthcare Investing What's Hot

Test Tube Liquid Inject 1

Acer Therapeutics Inc. (NASDAQ: ACER) shares jumped more than 10% after the Company announced together with its collaboration partner, RELIEF THERAPEUTICS Holding SA, that the China National Intellectual Property Administration (CNIPA) issued Electronic Patent Certificate ZL202122004991.9 on May 24, 2022, for Utility Model directed to ACER-001 (sodium phenylbutyrate). Specifically, the newly issued patent covers dosage form claims related to ACER-001’s polymer coated formulation for oral administration as a potential treatment for urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD). The newly issued patent has an expiration date of August 24, 2031.

“The receipt of this patent from the CNIPA for ACER-001, is an important milestone for Acer and Relief, adding key protection to the growing intellectual portfolio of this coated formulation of sodium phenylbutyrate, which could be an important treatment for patients with UCDs and we hope to extend its use as a potential treatment for MSUD and other indications. The issuance of this patent also marks an important step in our pursuit of possible ACER-001 commercialization in China.”

Raghuram (Ram) Selvaraju, Chairman of Relief

Acer Therapeutics is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. As for ACER-001, it is being developed for the treatment of various inborn errors of metabolism, including UCDs and Maple Syrup Urine Disease (MSUD). ACER-001 is a nitrogen-binding agent in development for use as adjunctive therapy in the chronic management of patients with UCDs involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS).